Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regression of neovascular iris vessels by intravitreal injection of bevacizumab.

× No keyword cloud information.

27 in total

Review 1. Medical and surgical treatment of neovascular glaucoma.

Authors: Lisa C Olmos; Richard K Lee
Journal: Int Ophthalmol Clin Date: 2011

2. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors: L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal: Eye (Lond) Date: 2015-12-18 Impact factor: 3.775

3. Combined pars plana vitrectomy and Baerveldt glaucoma implant placement for refractory glaucoma.

Authors: Thalmon R Campagnoli; Sung Soo Kim; William E Smiddy; Steve J Gedde; Donald L Budenz; Richard K Parrish; Paul F Palmberg; William Feuer; Wei Shi
Journal: Int J Ophthalmol Date: 2015-10-18 Impact factor: 1.779

4. Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.

Authors: Julia Lüke; Khaled Nassar; Salvatore Grisanti; Matthias Lüke
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-11-07 Impact factor: 3.117

5. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.

Authors: Yosuke Sugimoto; Hideki Mochizuki; Hideaki Okumichi; Masaya Takumida; Michiya Takamatsu; Seiichi Kawamata; Yoshiaki Kiuchi
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-06-04 Impact factor: 3.117

6. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.

Authors: Tomoaki Tatsumi; Shuichi Yamamoto; Juntaro Uehara; Takeshi Sugawara; Takayuki Baba; Masayuki Inoue; Hiroko Hata; Yoshinori Mitamura
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-12-19 Impact factor: 3.117

7. Intravitreal bevacizumab: an analysis of the evidence.

Authors: Derrick P Smit; David Meyer
Journal: Clin Ophthalmol Date: 2007-09

8. Short-term topical bevacizumab in the treatment of stable corneal neovascularization.

Authors: Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Andre Okanobo; Kraig S Bower; Denise S Ryan; Francisco Amparo; William Stevenson; Pedram Hamrah; Nambi Nallasamy; Reza Dana
Journal: Am J Ophthalmol Date: 2012-09-08 Impact factor: 5.258

9. Intravitreal bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report.

Authors: Tarek Alasil; Michael E Rauser
Journal: Cases J Date: 2009-10-30

10. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma.

Authors: Dimitrios Brouzas; Antonios Charakidas; Marilita Moschos; Chryssanthi Koutsandrea; Michael Apostolopoulos; Stefanos Baltatzis
Journal: Clin Ophthalmol Date: 2009-12-29